The Impact of Local Intervention Combined with Targeted Therapy on Metastatic Renal Cell Carcinoma

被引:15
作者
Li, Jian-Ri [1 ,2 ,3 ]
Ou, Yen-Chuan [4 ]
Yang, Cheng-Kuang [1 ]
Wang, Shian-Shiang [1 ,2 ,5 ]
Chen, Chuan-Su [1 ,2 ]
Ho, Hao-Chung [1 ]
Cheng, Chen-Li [1 ,2 ]
Yang, Chi-Rei [6 ]
Chen, Cheng-Che [1 ]
Wang, Shu-Chi [1 ]
Lin, Chia-Yen [1 ]
Hung, Sheng-Chun [1 ]
Hsu, Chiann-Yi [7 ]
Chiu, Kun-Yuan [1 ]
机构
[1] Taichung Vet Gen Hosp, Dept Surg, Div Urol, Taichung, Taiwan
[2] Chung Shan Med Univ, Inst Med, Taichung, Taiwan
[3] Hung Kuang Univ, Dept Med & Nursing, Taichung, Taiwan
[4] Tungs Taichung Metro Harbor Hosp, Taichung, Taiwan
[5] Natl Chi Nan Univ, Dept Appl Chem, Nantou, Taiwan
[6] China Med Univ Hosp, Dept Urol, Taichung, Taiwan
[7] Taichung Vet Gen Hosp, Dept Med Res, Taichung, Taiwan
关键词
Local intervention; metastasectomy; metastatic renal cell carcinoma; targeted therapy; METASTASECTOMY; RESECTION; SUNITINIB; EFFICACY;
D O I
10.21873/anticanres.12861
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background/Aim: We performed a retrospective survey on our metastatic renal cell carcinoma (MRCC) patients who had received targeted therapies, and afterwards evaluated the clinical impacts of local interventions on the patient outcomes. Materials and Methods: Between 2006 and 2016, 124 patients with MRCC who had received at least one line of tyrosine kinase inhibitors or mammalian target of rapamycin were included in the study. Seventy-five patients (60.5%) received targeted therapies only, twenty-six patients received complete resection and the remaining 23 received incomplete local interventions for their metastatic lesions. Analysis of the basic characteristics, overall survival and multi-variant regression amongst the three groups was performed. Results: The age, gender distribution, tumor cell type, targeted therapy selection, line of therapies and sites of metastases were not different amongst the three groups. The targeted therapy-only group had a significantly higher percentage of Memorial Sloan Kettering Cancer Center (MSKCC) poor-risk patients compared with the other two groups (22.7% vs. 3.8% and 0%, p=0.006 respectively). The targeted treatment duration and follow-up duration was significantly shorted in the targeted therapy-only group. Of the twelve variables analyzed, complete resection and MSKCC poor-risk group showed a significant impact on the overall survival rate (HR=0.5, 95%CI=0.25-0.98, p=0.045; HR=2.97, 95%CI= 1.05-8.4, p=0.04 respectively). Conclusion: Complete resection of metastatic sites for MRCC patients, combined with targeted therapy, could provide better overall survival rates than targeted therapy alone. Poor MSKCC risk is still correlated to a poor outcome in the current targeted therapy era.
引用
收藏
页码:5339 / 5345
页数:7
相关论文
共 18 条
  • [2] Brehmer B, 2016, WORLD J UROL, V34, P1061, DOI 10.1007/s00345-016-1865-8
  • [3] Local treatments for metastases of renal cell carcinoma: a systematic review
    Dabestani, Saeed
    Marconi, Lorenzo
    Hofmann, Fabian
    Stewart, Fiona
    Lam, Thomas B. L.
    Canfield, Steven E.
    Staehler, Michael
    Powles, Thomas
    Ljungberg, Boerje
    Bex, Axel
    [J]. LANCET ONCOLOGY, 2014, 15 (12) : E549 - E561
  • [4] The Efficacy of Wide Resection for Musculoskeletal Metastatic Lesions of Renal Cell Carcinoma
    Higuchi, Takashi
    Yamamoto, Norio
    Hayashi, Katsuhiro
    Takeuchi, Akihiko
    Kato, Satoshi
    Miwa, Shinji
    Abe, Kensaku
    Taniguchi, Yuta
    Aiba, Hisaki
    Tsuchiya, Hiroyuki
    [J]. ANTICANCER RESEARCH, 2018, 38 (01) : 577 - 582
  • [5] Complete metastasectomy for renal cell carcinoma: Comparison of five solid organ sites
    Jakubowski, Christopher D.
    Vertosick, Emily A.
    Untch, Brian R.
    Sjoberg, Daniel
    Wei, Elizabeth
    Palmer, Frank L.
    Patel, Snehal G.
    Downey, Robert J.
    Strong, Vivian E.
    Russo, Paul
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2016, 114 (03) : 375 - 379
  • [6] Metastasectomy After Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
    Karam, Jose A.
    Rini, Brian I.
    Varella, Leticia
    Garcia, Jorge A.
    Dreicer, Robert
    Choueiri, Toni K.
    Jonasch, Eric
    Matin, Surena F.
    Campbell, Steven C.
    Wood, Christopher G.
    Tannir, Nizar M.
    [J]. JOURNAL OF UROLOGY, 2011, 185 (02) : 439 - 444
  • [7] Spinal Metastasectomy of Renal Cell Carcinoma: A 16-Year Single Center Experience With a Minimum 3-Year Follow-Up
    Kato, Satoshi
    Murakami, Hideki
    Demura, Satoru
    Nambu, Koshi
    Fujimaki, Yoshiyasu
    Yoshioka, Katsuhito
    Kawahara, Norio
    Tomita, Katsuro
    Tsuchiya, Hiroyuki
    [J]. JOURNAL OF SURGICAL ONCOLOGY, 2016, 113 (05) : 587 - 592
  • [8] Li JR, 2014, ANTICANCER RES, V34, P5643
  • [9] Efficacy of everolimus in advanced renal cell carcinoma:: a double-blind, randomised, placebo-controlled phase III trial
    Motzer, Robert J.
    Escudier, Bernard
    Oudard, Stephane
    Hutson, Thomas E.
    Porta, Camillo
    Bracarda, Sergio
    Gruenwald, Viktor
    Thompson, John A.
    Figlin, Robert A.
    Hollaender, Norbert
    Urbanowitz, Gladys
    Berg, William J.
    Kay, Andrea
    Lebwohl, David
    Ravaud, Alain
    [J]. LANCET, 2008, 372 (9637) : 449 - 456
  • [10] Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial
    Motzer, Robert J.
    Rini, Brian I.
    McDermott, David F.
    Redman, Bruce G.
    Kuzel, Timothy M.
    Harrison, Michael R.
    Vaishampayan, Ulka N.
    Drabkin, Harry A.
    George, Saby
    Logan, Theodore F.
    Margolin, Kim A.
    Plimack, Elizabeth R.
    Lambert, Alexandre M.
    Waxman, Ian M.
    Hammers, Hans J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (13) : 1430 - 1437